Skip to Main Content

Current Clinical Trials

Breast

Title Status

Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer

Principal Investigator: Danielle Bertoni, MD

Click here for more information on this trial.

Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Principal Investigator: Danielle Bertoni, MD

Click here for more information on this trial.

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Principal Investigator: Norman Yeh, MD

Click here for more information on this trial.

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)

Principal Investigator: Norman Yeh, MD

Click here for more information on this trial.

Pacific Northwest Breast Cancer Screening Research

Principal Investigator: Jessica Germino, MD 

Click here for more information on this trial.


Lung

Title Status

Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Principal Investigator: John Strother, MD

Click here for more information on this trial.

Crizotinib in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Principal Investigator: John Strother, MD

Click here for more information on this trial.

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Principal Investigator: John Strother, MD

Click here for more information on this trial.

Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Principal Investigator: Norman Yeh, MD

Click here for more information on this trial.

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Principal Investigator: John Strother, MD

Click here for more information on this trial.

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Principal Investigator: John Strother, MD

Click here for more information on this trial.

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Principal Investigator: John Strother, MD

Click here for more information on this trial.


Other

Disease Site Title Status
Advanced Cancers  NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Principal Investigator: John Strother, MD

Click here for more information on this trial.
Bladder

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Principal Investigator: John Strother, MD

Click here for more information on this trial.
Head and neck

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin

Principal Investigator: John Strother, MD

Click here for more information on this trial.
Cholangiocarcinoma

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Principal Investigator: John Strother, MD

Click here for more information on this trial.
 Breast or Gynecologic Cancer

Opening the Conversation: A study for reproductive-aged cancer survivors and their partners

Principal Investigator: Jessica Germino, MD 

Click here for more information on this trial.
 Multiple Myeloma

A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/ Refractory Multiple Myeloma (RRMM) (DREAMM3)

Principal Investigator: John Strother, MD

Click here for more information on this trial.

To learn more about cancer clinical trials available, visit clinicaltrials.gov.

 

Disease Site Title Status
Patients with Paroxysmal Supraventricular Tachycardia

Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia

Principal Investigator: Jeff Hsing, MD

Click here for more information on this trial.
Title Status

Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry (COVID-19)

Principal Investigator: Brian Delmonaco, MD

Click here for more information on this trial.

A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)

Principal Investigator: Brian Delmonaco, MD

Click here for more information on this trial.

ASCO Survey on COVID-19 in Oncology (ASCO) Registry

Principal Investigator: Nicholas Tedesco, DO

Click here for more information on this trial.

 

Disease Site Title Status
Patients with Psoriatic Arthritis 

A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with active psoriatic arthritis

Principal Investigator: Jonathan Jones, MD

Click here for more information on this trial.
Patients with Rheumatoid Arthritis 

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

Principal Investigator: Jonathan Jones, MD

Click here for more information on this trial.

 

Condition Title Status
Insulin Sensitivity, Obesity and Sedentary Lifestyle

Exercise and Insulin Signaling in Human Skeletal Muscle

Samaritan Health Services Principal Investigators: Craig Graham, MD, Nicholas Phillips, MD, and Josh Lenhof, DO


Oregon State University Principal Investigators: Sean Newsom, PhD, and Matthew Robinson, PhD

Click here for more information on this trial or review an informational flyer.

For more information about clinical research at Samaritan, contact us at 541-768-4352 or clinicalresearch@samhealth.org.